NCT04116658: A trial that was reported late by Enterome
This trial has reported, although it was 195 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04116658 |
|---|---|
| Title | A Multicenter, Open-Label, First-in-Human, Phase 1b/2a Trial of EO2401, a Novel Multipeptide Therapeutic Vaccine, With and Without Check Point Inhibitor, Following Standard Treatment in Patients With Progressive Glioblastoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 13, 2020 |
| Completion date | March 4, 2024 |
| Required reporting date | March 4, 2025, midnight |
| Actual reporting date | Sept. 15, 2025 |
| Date last checked at ClinicalTrials.gov | May 29, 2026 |
| Days late | 195 |